Martin Shkreli, the hedge fund manager-turned-pharmacological profiteer, rocketed into the national consciousness on the back of an astronomical drug price increase. Daraprim is a medicine used to treat toxoplasmosis, particularly in patients with HIV, and it can also sometimes work as an antimalarial. After Shkreli's Turing Pharmaceuticals acquired the drug in 2015, Daraprim rose in price from $13.50 to $750. In November, some high-school aged students in Sydney, Australia, synthesized an equivalent drug, at an estimated cost of just $2 a dosage.

From Inverse:

The students, from Sydney Grammar School, announced their work on Wednesday at the Royal Australian Chemical Institute NSW Organic Chemistry Symposium. Their research was done with the help of their chemistry teacher together with the University of Sydney chemist Alice Williamson, Ph.D., who collaborated with them through a website called Open Source Malaria, a platform for treating the mosquito-borne disease using readily available drugs.